The Europe hematology analyzers and reagents market is expected to reach US$ 3,601.88 million by 2027 from US$ 2,037.24 million in 2019. The market is estimated to grow at a CAGR of 7.5% from 2020 to 2027.
The growth of this market can be attributed to key driving factors, such as rising demand for organ transplantation and increasing organic and inorganic strategies regarding hematology analyzers and reagents. However, the market growth is likely to be hindered owing to the recalls of damaged hematology analyzers and reagents by manufacturers.
The demand for hematology analyzers and reagents is growing significantly, which can be attributed to increasing preference for hematology testing during transplantation, rising research activities on hematology analyzers and reagents, and surging demand for blood and blood components. The Spanish National Transplant Organization (ONT) reached a rate of 48 donors per million population and surpassed 5,300 organ transplants, including all-time highs in kidney and lung transplantation. The organization demonstrated its ability to continually improve in 2018 by reaching 48 donors per million population (p.m.p.), 2,243 donors enabling 5,314 organs to be transplanted.
According to statistics gathered by the German Organ Transplantation Foundation—on whose data all the following transplant numbers are based—9,000 people in Germany were waiting for an organ to become available in 2018. In 2019, 3,767 organs were transplanted in Germany, 574 of which were living-donor transplants. The majority of cases involved kidney transplants (56.6%), followed by liver transplants (22.1%) and similar rates of the lung (9.6%) and heart transplants (9.1%). Less common are transplantations of the pancreas (2.5%) and small intestine (0.1%). At the same time, transplant Anti-HLA alloantibodies play an essential role in several pathologic processes. In certain hematology patients, anti-HLA antibody testing is important for the appropriate selection of allogeneic HPC or platelet donors. Rising demand for organ transplantation is augmenting the growth of the hematology analyzers and reagents market.
Blood donation saves lives. European countries, amidst the coronavirus pandemic, majorly need blood. However, there exists a converse scenario in Europe as the number of people donating blood has dropped due to the fear of getting an infection. The blood services in the Europe continue to operate during the emergency situation for helping the patients with blood products every day. Large blood donation drives are usually conducted in universities, hospitals, and corporate offices. However, the shuttering of these organizations has created a significant dip in the number of blood donations within the region. The outbreak has severely hit countries, such as Italy, Spain, Germany, France, and the UK. To respond to the pandemic, the majority of the healthcare research institutes and pharmaceutical companies are stepping forward to discover a therapeutic solution for the disease. Companies are now focusing on the development of the antibody-specific COVID-19 blood test. Rising number of blood tests performed for coronavirus diagnosis is likely to boost the demand for hematology analyzers and reagents in the region.
Based on product and service, the Europe hematology analyzers and reagents market is segmented into hematology products and services, hemostasis products and services, and immunohematology products and services. The hematology products and services segment is further divided into instruments, reagents and consumables, and services. The hemostasis products and services segment is further divided into instruments, reagents and consumables, and services. The immunohematology products and services segment is further divided into instruments, reagents and consumables, and services. The hematology products and services segment held the largest market share in 2019, and the same segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on application, the Europe hematology analyzers and reagents market is categorized into anemia, blood cancer, hemorrhagic conditions, infection related conditions, immune system related conditions, and others. The anemia segment held a larger market share in 2019, whereas the blood cancer segment is anticipated to register a higher CAGR in the market during 2020–2027.
Based on end user, the Europe hematology analyzers and reagents market is segmented into hospital laboratories, commercial service providers, government reference laboratories, and research and academic institutes. In 2019, the hospital laboratories segment held the largest share of the market, and the same segment is anticipated to register the highest CAGR in the market from 2020 to 2027.
Primary and secondary sources referred to while preparing the report on the Europe hematology analyzers and reagents market include German Organ Transplantation Foundation and National Registry of Congenital Coagulopathies.